Assessment of Response to Concomitant Chemoradiation with Capecitabine in Locally Advanced Rectal Carcinoma: A Descriptive Observational Study from Nishtar Hospital, Multan

Objective: To assess the response of preoperative concomitant chemo-radiation with capecitabine in patientswith locally advanced rectal carcinoma.Study Design: A descriptive observational study.Place and Duration of Study: This study was conducted at the Department of Oncology, Nishtar Hospital,Multan, Pakistan from 5th November 2024 to 5th May 2025.Methods: A total of 100 patients aged 18-70 years old, diagnosed with stage 3 or 4 non-metastatic rectaladenocarcinoma, were included. Protracted radiotherapy at 50.4 Gray was delivered over 5.5 weeks, with 1.8Gray per session, five days a week. An 825 mg/m2 dose of Capecitabine was administered orally twice a daythrough the radiotherapy course, including weekends, along with the start of radiotherapy. Surgery wasperformed 4-6 weeks after the concurrent treatment and the technique was chosen according to the surgeon'sdiscretion. Adjuvant chemotherapy of four cycles of IV 5-FU (400 mg/m2) and leucovorin (20 mg/ m2) wasstarted four to six weeks postoperatively.Results: Frequent grade I and II toxicity included anemia (70%), abdominal pain (50%), proctitis (42%), andnausea (46%). Capecitabine treatment was stopped in 25 patients due to grade III and IV diarrhea (37%),abdominal pain (14%), and proctitis (33%), but it did not have a significant impact on compliance. Theradiotherapy compliance was 90% and 93% capecitabine dose was administered as the total dose. A pathologiccomplete response was reached in 8 patients (8%). Tumor downstaging was achieved in 55% of patients, andnodal down staging was observed in 50% of patients.Conclusion: Concurrent chemoradiotherapy with capecitabine is a safe and well-tolerated treatment inpatients with locally advanced rectal cancer. It has comparable efficacy to 5-FU chemotherapy and can be usedas an alternative to achieve similar outcomes. How to cite this: Nasir F, Bashir A, Hassan MJ, Jamil T. Assessment of Response to Concomitant Chemoradiation with Capecitabine in Locally Advanced Rectal Carcinoma: A Descriptive Observational Study from Nishtar Hospital, Multan. Life and Science. 2025; 6(4): 483-489. doi: http://doi.org/10.37185/LnS.1.1.933

Authors

Institutions

Publication Details

Journal
Life and Science
Published
2025-10-08
DOI
https://doi.org/10.37185/lns.1.1.933
Primary Topic
Colorectal Cancer Surgical Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessment of Response to Concomitant Chemoradiation with Capecitabine in Locally Advanced Rectal Carcinoma: A Descriptive Observational Study from Nishtar Hospital, Multan

Aalia Bashir, Tariq Jamil, Muhammad Junaid Hassan, F. Nasir
Life and Science
Colorectal Cancer Surgical Treatments
article

Assessment of Response to Concomitant Chemoradiation with Capecitabine in Locally Advanced Rectal Carcinoma: A Descriptive Observational Study from Nishtar Hospital, Multan

Aalia Bashir, Tariq Jamil, Muhammad Junaid Hassan, F. Nasir
article en

Abstract

Objective: To assess the response of preoperative concomitant chemo-radiation with capecitabine in patientswith locally advanced rectal carcinoma.Study Design: A descriptive observational study.Place and Duration of Study: This study was conducted at the Department of Oncology, Nishtar Hospital,Multan, Pakistan from 5th November 2024 to 5th May 2025.Methods: A total of 100 patients aged 18-70 years old, diagnosed with stage 3 or 4 non-metastatic rectaladenocarcinoma, were included. Protracted radiotherapy at 50.4 Gray was delivered over 5.5 weeks, with 1.8Gray per session, five days a week. An 825 mg/m2 dose of Capecitabine was administered orally twice a daythrough the radiotherapy course, including weekends, along with the start of radiotherapy. Surgery wasperformed 4-6 weeks after the concurrent treatment and the technique was chosen according to the surgeon'sdiscretion. Adjuvant chemotherapy of four cycles of IV 5-FU (400 mg/m2) and leucovorin (20 mg/ m2) wasstarted four to six weeks postoperatively.Results: Frequent grade I and II toxicity included anemia (70%), abdominal pain (50%), proctitis (42%), andnausea (46%). Capecitabine treatment was stopped in 25 patients due to grade III and IV diarrhea (37%),abdominal pain (14%), and proctitis (33%), but it did not have a significant impact on compliance. Theradiotherapy compliance was 90% and 93% capecitabine dose was administered as the total dose. A pathologiccomplete response was reached in 8 patients (8%). Tumor downstaging was achieved in 55% of patients, andnodal down staging was observed in 50% of patients.Conclusion: Concurrent chemoradiotherapy with capecitabine is a safe and well-tolerated treatment inpatients with locally advanced rectal cancer. It has comparable efficacy to 5-FU chemotherapy and can be usedas an alternative to achieve similar outcomes. How to cite this: Nasir F, Bashir A, Hassan MJ, Jamil T. Assessment of Response to Concomitant Chemoradiation with Capecitabine in Locally Advanced Rectal Carcinoma: A Descriptive Observational Study from Nishtar Hospital, Multan. Life and Science. 2025; 6(4): 483-489. doi: http://doi.org/10.37185/LnS.1.1.933

Life and ScienceVol. 6(4)
Nishtar Medical College and Hospital (PK), Allama Iqbal Medical College (PK)
Openalex Percentile: Top 52%
Colorectal Cancer Surgical Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.